{"id":"W2989894179","doi":"10.1016/s1470-2045(19)30684-9","title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":644,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"Prostate Cancer UK; Public Health Agency; Division of Research, Evaluation, and Communication; Prostate Cancer Foundation; Movember Foundation; AstraZeneca; Medical Research Council; Institute of Cancer Research; Cancer Research UK; Royal Marsden NHS Foundation Trust; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; U.S. Department of Veterans Affairs","keywords":"Olaparib; Medicine; Prostate cancer; Open label; Oncology; Internal medicine; Urology; Cancer; Randomized controlled trial; Gene; Biology; Poly ADP ribose polymerase; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006505047,0.0002200703,0.0008185846,0.00009072928,0.0001439192,0.00004782209,0.0002112606,0.00005817339,0.0002245753],"category_scores_gemma":[0.0000498832,0.0001109792,0.0000323108,0.0003338486,0.0001579103,0.000176068,0.0000611533,0.0003144973,0.00003302783],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004377957,"about_ca_system_score_gemma":0.001497502,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003280822,"about_ca_topic_score_gemma":0.002995463,"domain_scores_codex":[0.99797,0.0003565329,0.0004101352,0.0003971546,0.0003486841,0.0005175379],"domain_scores_gemma":[0.998748,0.0002026843,0.0002208184,0.0004906395,0.0002119953,0.0001258563],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9596585,0.005033165,0.0270315,0.0001136391,0.0007090644,0.000144308,0.002624221,0.00008611616,0.001398922,0.00004545961,0.00112815,0.00202693],"study_design_scores_gemma":[0.964244,0.0114346,0.01519254,0.0001410509,0.0003702222,0.000008330198,0.0002920953,0.0004464103,0.0007590284,0.00001536897,0.006911413,0.0001849488],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857726,0.0003149389,0.000005262122,0.002262568,0.0001429689,0.01005902,0.00009013608,0.00004278644,0.001309749],"genre_scores_gemma":[0.9915929,0.0001353357,0.001957831,0.0005485338,0.0001510195,0.002267541,0.000337105,0.00003710777,0.002972645],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01183896,"threshold_uncertainty_score":0.45256,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06985848620486315,"score_gpt":0.3983035503391584,"score_spread":0.3284450641342952,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}